# Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis

> **NCT03020199** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 196 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **BIOLOGICAL:** Secukinumab
- **RADIATION:** nb-UVB

## Key facts

- **NCT ID:** NCT03020199
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-27
- **Primary completion:** 2021-11-30
- **Final completion:** 2023-06-16
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2025-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03020199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03020199, "Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03020199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*